Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

A Split-Scar Study: Study of Surgical Scar Using Exosomes

Jeong KH., Park KY., Jung DW.

Prospective Study on Chronic Wound, Scar, published in J Cosmet Dermatol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Cosmet Dermatol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41748500
PMCID
PMC12945872
DOI
10.1111/jocd.70756
Citations
1

Abstract (original English)

Background Exosomes have emerged as a promising therapeutic agent for various dermatological conditions such as acne, atopic dermatitis, and wound healing. This study aims to evaluate exosome's efficacy in improving postoperative scars. Methods Ten patients underwent revision rhinoplasty with autologous costal cartilage, each with a 3 cm anterior chest incision scar were enrolled. Scars (mean 4.3 months postoperatively) were divided into medial and lateral halves; one half was treated with ASC-Exosome (experimental) and the other with hyaluronic acid (control). Outcomes were assessed using the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS). Result The experimental side treated with ASC-Exosome demonstrated improvements compared to the control side. Pigmentation improved significantly in the Observer Scar Assessment Scale (OSAS) group from week 3 onward, though no consistent changes were observed on the VSS. Pliability showed significant improvement in both OSAS and VSS, beginning at week 3 and persisting through week 8. Relief also improved in the OSAS group from weeks 4 to 8. While no vascularity differences were detected, one-year follow-up photographs confirmed superior improvements in scar height and thickness on the exosome-treated side. Patient Scar Assessment Scale (PSAS) indicated significant improvements in scar color by week 4, s

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
CicatrixHumansPostoperative ComplicationsHyaluronic AcidTreatment OutcomeRhinoplastyReoperationTransplantation, AutologousFollow-Up StudiesAdult

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research